| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |